Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 11, 2005, Pages 4072-4078

  Berdugo, Marianne ^a   Andrieu Soler, Charlotte ^a,b   Doat, Marc ^a   Courtois, Yves ^a   BenEzra, David ^c   Behar Cohen, Francine ^a,d  

^a INSERM   (France)

^b Optis France   (France)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; CYCLOOXYGENASE 2 INHIBITOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; MESSENGER RNA; VASCULOTROPIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; INTERLEUKIN 1; PHOSPHOPROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORNEA NEOVASCULARIZATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; CONJUNCTIVA; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; GENETICS; GERMFREE ANIMAL; INJECTION; LEWIS RAT; METABOLISM; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; IMMUNOHISTOCHEMISTRY; INJECTIONS; INTERLEUKIN-1; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PHOSPHOPROTEINS; RATS; RATS, INBRED LEW; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644669648     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0105     Document Type: Article

References (40)

1. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta. 1990;1049:99-125.
2. Cohen JS. Antisense oligodeoxynucleotides as antiviral agents. Antiviral Res. 1991;16:121-133.
3. Crooke ST. Therapeutic applications of oligonucleotides. Biotechnology. 1992;10:882-886.
4. Milligan JF, Matteucci MD, Martin JC. Current concepts in antisense drug design. J Med Chem. 1993;36:1923-1937.
5. Orr RM. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA Vision. Curr Opin Mol Ther. 2001;3:288-394.
6. Kitajima I, Unoki K, Maruyama I. Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo. Antisense Nucleic Acid Drug Dev. 1999;9:233-239.
7. White MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997;40(suppl 2):S2-S17.
8. White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res. 1998;53:119-138.
9. Shpakov AO, Pertseva MN. Structural and functional characterization of insulin receptor substrate proteins and the molecular mechanisms of their interaction with insulin superfamily tyrosine klnase receptors and effector proteins. Membr Cell Biol. 2000;13:455-484.
10. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:435-444.
11. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem. 2000;275:21695-21702.
12. Jiang ZY, He Z, King BL, et al. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem. 2003;278:31964- 31971.
13. Slomiany MG, Rosenzweig SA. Autocrine effects of IGF-1-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am J Physiol. 2004;287:C746-C753.
14. Bermont L, Lamielle F, Lorchel F, et al. Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. J Clin Endocrinol Metab. 2001;86:363-368.
15. Senthil D, Ghosh Choudhury G, Bhandari BK, Kasinath BS. The type 2 vascular endothelial growth factor receptor recruits insulin receptor substrate-1 in its signalling pathway. Biochem J. 2002;368:49-56.
16. Vuori K, Ruoslahti E. Association of insulin receptor substrate-1 with integrins. Science. 1994;266:1576-1578.
17. BenEzra D, Hemo I, Maftzir G. In vivo angiogenic activity of interleukins. Arch Ophthalmol. 1990;108:573-576.
18. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
19. Yamada J, Dana MR, Sotozono C, Kinoshita S. Local suppression of IL-I by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res. 2003;76:161-167.
20. Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 2004;18:161-163.
21. Fan F, Stoeltzing O, Liu W, et al. Interleukin-1beta regulates angiopoietin-1 expression in human endothelial cells. Cancer Res. 2004;64:3186-3190.
22. Wallace WC, Akar CA, Lyons WE, Kole HK, Egan JM, Wolozin B. Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity. Brain Res Mol Brain Res. 1997;52:213-227.
23. Drygin D, Barone S, Bennett CF. Sequence-dependent cytotoxicity of second-generation oligonucleotides. Nucleic Acids Res. 2004;32:6585-6594.
24. Poulaki V, Qin W, Joussen AM, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest. 2002;109:805-815.
25. Usui T, Ishida S, Yamashiro K, et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004;45:368-374.
26. Neid M, Datta K, Stephan S, et al. Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J Biol Chem. 2004;279:3941-3948.
27. BenEzra D, Griffin BW, Maftzir G, Sharif NA, Clark AP. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci. 1997;38:1954-1962.
28. Moore JE, McMullen TC, Campbell IL, et al. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest Ophthalmol Vis Sci. 2002;43:2905-2915.
29. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 2003;100:2645-2650.
30. Kuwano T, Nakao S, Yamamoto H, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 2004;18:300-310.
31. Rabinovsky ED, Draghia-Akli R. Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis. Mol Ther. 2004;9:46-55.
32. Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol. 2002;169:469-475.
33. Seo KH, Ko HM, Choi JH, et al. Essential role for platelet-activating factor-induced NF-kappaB activation in macrophage-derived angiogenesis. Eur J Immunol. 2004;34:2129-2137.
34. Yoshida S, Yoshida A, Matsui H, Takada Y, Ishibashi T. Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. Lab Invest. 2003;83:927-938.
35. Kwon YW, Jang ER, Lee YM, et al. Insulin-like growth factor II induces interleukin-6 expression via NFkappaB activation in psoriasis. Biochem Biophys Res Commun. 2000;278:312-317.
36. Waters SB, Pessin JE. Insulin receptor substrate 1 and 2 (IRS1 and IRS2): what a tangled web we weave. Trends Cell Biol. 1996;6:1-4.
37. Giovannone B, Scaldaferri ML, Federici M, et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev. 2000;16:434-441.
38. Huang SS, Leal SM, Chen CL, Liu IH, Huang JS. Cellular growth inhibition by TGF-beta1 involves IRS proteins. FEBS Lett. 2004;565:117-121.
39. Zheng B, Clemmons DR. Blocking ligand occupancy of the alphaV-beta3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells. Proc Natl Acad Sci USA. 1998;95:11217-11222.
40. Shaw LM. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol. 2001;21:5082-5093.